Sign In  |  Register  |  About Daly City  |  Contact Us

Daly City, CA
September 01, 2020 1:20pm
7-Day Forecast | Traffic

  • Search Hotels in Daly City

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Veracyte Inc (NQ: VCYT )

26.67 -1.22 (-4.37%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 3, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 551,822
Open 26.57
Bid (Size) 25.13 (1)
Ask (Size) 28.04 (1)
Prev. Close 27.89
Today's Range 25.80 - 27.52
52wk Range 14.85 - 33.23
Shares Outstanding 67,473,870
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Veracyte Announces Multiple Decipher Urologic Testing Abstracts to be Presented at the 2023 ASCO Genitourinary (GU) Cancers Symposium
From Veracyte, Inc.
Via Business Wire
Veracyte Announces New Data Suggesting Afirma Testing Can Help Personalize Care for Patients with Thyroid Nodules
From Veracyte, Inc.
Via Business Wire

Performance

YTD
+17.75%
+17.75%
1 Month
+12.20%
+12.20%
3 Month
+9.39%
+9.39%
6 Month
-4.41%
-4.41%
1 Year
-3.75%
-3.75%

More News

Read More
Better Long-Term Buy in 2023: Exact Sciences or Veracyte?
Via The Motley Fool
Exagen Inc. Elects Tina S. Nova, Ph.D. as Executive Chair of the Board of Directors
From Exagen Inc.
Via Globe NewsWire
Expert Ratings for Veracyte
Via Benzinga
Veracyte Earnings Perspective: Return On Capital Employed
Via Benzinga
Raymond James Upgrades Natera & Myriad Genetics, While Downgrading This Stock
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For January 18, 2023
Via Benzinga
This Small-Cap Stock Is a No-Brainer Buy
Via The Motley Fool
Data Published in JCEM Demonstrate Strong Real-World Performance of Veracyte’s Afirma GSC in Thyroid Cancer Diagnosis
From Veracyte, Inc.
Via Business Wire
Veracyte Stock Showing Market Leadership; Earns 93 RS Rating
Via Investor's Business Daily
US Stocks Open Lower; Nasdaq Drops 100 Points
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For January 5, 2023
Via Benzinga
Why Apyx Medical Shares Dipped Over 60%; Here Are 123 Biggest Movers From Yesterday
Via Benzinga
Why Greenhill Shares Climbed Around 25%; Here Are 100 Biggest Movers From Yesterday
Via Benzinga
Why Lincoln National Shares Are Trading Lower By 31%? Here Are 72 Stocks Moving In Thursday's Session
Via Benzinga
Veracyte Announces Third Quarter 2022 Financial Results
From Veracyte, Inc.
Via Business Wire
Earnings Scheduled For November 2, 2022
Via Benzinga
Veracyte Announces Three Abstracts to Be Presented at SITC 2022 Annual Meeting
From Veracyte, Inc.
Via Business Wire
Veracyte to Participate in the Credit Suisse 31st Annual Healthcare Conference
From Veracyte, Inc.
Via Business Wire
New Data Suggest Decipher GRID-Derived Genomic Signature Can Help Identify Men with Prostate Cancer Who Should Receive High-Dose Radiotherapy
From Veracyte, Inc.
Via Business Wire
Veracyte Data Presented at ATA Annual Meeting Provide New Insights into Molecular Underpinnings of Thyroid Cancer
From Veracyte, Inc.
Via Business Wire
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
New Data Presented at CHEST 2022 Reinforce Clinical Value of Veracyte’s Genomic Tests in Interstitial Lung Disease and Lung Cancer
From Veracyte, Inc.
Via Business Wire
Veracyte to Release Third Quarter 2022 Financial Results on November 2, 2022
From Veracyte, Inc.
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 DalyCity.com & California Media Partners, LLC. All rights reserved.